Orthox Ltd.

Founded in 2009 to commercialise technology developed at Oxford University, Orthox aims to revolutionise the way Osteoarthritis (OA) is treated. This debilitating disease, caused by erosion of the smooth, stiff cartilage in our joints, affects over 300 million globally and costs the US economy alone over $128 billion each year. 

Current therapies to repair damaged cartilage focus either on tissue regeneration or on functional replacement; Orthox’s exceptionally strong, resilient, regenerative hydrogel technology, FibroFix™  achieves both these goals, offering a unique solution for the millions of OA patients unsuitable or unprepared for the major surgery needed to implant a metal and plastic joint replacement.

Initially targeting OA in the knee joint, a condition which affects over 40 million sufferers in the EU & US, Orthox has developed a compelling set of data on FibroFix™ funded by €6.5m investment and over €11m in grants. FibroFix™ technology will be rolled out to treat OA other joints and Orthox also has pipeline developments beyond orthopaedics where strength and tissue regeneration are key.

Pipeline expansion is valuable as growth in the annual global biomaterials market will exceed $250 billion by 2025. Orthopaedic biomaterials will form the largest proportion of this and natural biomaterials, like FibroFix™, will be the fastest growing market segment (Grand View Research 4751754).

Orthox: Reducing Pain, Increasing Mobility, Regenerating Strength™.